Physician profile
Mark P Crick
NPI 1003801895
$9,432.67
in general payments reported to CMS, 2019-2025
53 companies · $2,349 in 2025
The $2,349 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $572 · 2021: $1,550 · 2022: $2,659 · 2023: $1,619 · 2024: $121 · 2025: $2,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,293.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,147.16 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $920.06 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $601.75 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $553.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $478.27 | 2021-2025 | Shingrix, Arexvy, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.94 | 2020-2025 | Jardiance, Ofev |
| Esperion Therapeutics, INC. | $293.84 | 2021-2025 | Nexletol |
| Pfizer INC. | $278.22 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.37 | 2022-2023 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $227.97 | 2022-2025 | Rexulti, Nuedexta |
| Kowa Pharmaceuticals America, INC. | $223.75 | 2019-2023 | Seglentis, Livalo |
| Novartis Pharmaceuticals Corporation | $194.79 | 2021-2025 | |
| Antares Pharma, INC. | $174.67 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $159.16 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Crick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.